Europe is losing the race for innovative drugs

In 2024, China and the USA led the introduction of new active substances in the pharmaceutical market, with Europe lagging behind. Factors contributing to China's success include competitive approaches, lower research costs, and a supportive government strategy. Europe faces challenges due to high costs and a fragmented regulatory system, making it difficult to compete. However, Europe has strong academic institutions and accumulated knowledge that could help regain its position. To compete effectively, Europe needs to enhance investments in R&D, streamline procedures, and create a unified innovation ecosystem. Without addressing these issues, Europe risks falling further behind in the global pharmaceutical race.